Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study
- 1 May 1999
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 21 (1) , 20-25
- https://doi.org/10.1097/00126334-199905010-00003
Abstract
This study was conducted to evaluate the efficacy of highly active antiretroviral therapy (HAART) in preventing recurrence of oral candidosis (OC) associated with HIV. A prospective case-controlled observational study was performed in an inner-city university-hospital HIV/AIDS clinic. Ninety-three HIV-positive study subjects with a history of recurrent OC were divided into two groups: protease inhibitors (PI)-treated patients (group 1, n = 30) and non-PI-treated patients (group 2, n = 63). Study subjects were matched for sex, age, stage of HIV infection, and peripheral CD4+ T-cell counts. The non-PI-treated group was further subdivided into the following three subgroups: HIV-positive study subjects treated with reverse transcriptase inhibitors (RTI; groups 2a and 2c) and HIV-positive study subjects not treated with RTIs (group 2b). Group 2c met the same inclusion criteria as group 2a had but was matched 6 months after the beginning of the study. We also assessed in vitro peripheral blood mononuclear cells (PBMC) and their lymphoproliferative response, as well as cutaneous delayed-type hypersensitivity (DTH) response to Candida-associated antigens in a randomly selected sample of study subjects divided into those treated with PIs and those who were not. During a 1-year follow-up, OC was diagnosed in 2 (7%) PI-treated and 23 (36%) non-PI-treated patients (p < .001). In addition to comparing findings in group 1 with those in group 2c, OC was detected in 14 (50%) non-PI-treated patients compared with no HAART-treated study subjects (p < .001). Only 41% of PI-treated study subjects had positive lymphoproliferative response in PBMCs and none was positive in terms of DTH to Candida antigens (p = not significant versus non-PItreated study subjects). While objectively demonstrating a beneficial effect of HAART in preventing recurrence of OC infections, our findings suggest this effect cannot be not fully accounted for by reconstitution of anti-Candida cell-mediated immunity, given that other mechanisms, even of a nonimmune nature, could have some effect.Keywords
This publication has 14 references indexed in Scilit:
- Evidence that Members of the Secretory Aspartyl Proteinase Gene Family, in ParticularSAP2,Are Virulence Factors forCandidaVaginitisThe Journal of Infectious Diseases, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapyThe Lancet, 1998
- Effect of HAART on natural history of AIDS-related opportunistic disordersThe Lancet, 1998
- HIV-1 protease inhibitors. A review for cliniciansJAMA, 1997
- Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infectionJournal of Antimicrobial Chemotherapy, 1996
- Resolution of Refractory AIDS-Related Mucosal Candidiasis after Initiation of Didanosine plus SaquinavirNew England Journal of Medicine, 1996
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996
- PUTATIVE VIRULENCE FACTORS OF CANDIDA ALBICANSAnnual Review of Microbiology, 1991
- Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjectsClinical and Experimental Immunology, 1991